OPKO HealthOPK -0.98%52 Buyback Yield % is 4.47 as of Jul. 02, 2026, which is 21% below its 10-year median of 5.68. GuruFocus rates OPK with a GF Score™ of 52/100 and a GF Value™ of $1.06 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 89 Medical Diagnostics & Research companies, OPKO Health ranks better than 94.38% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for OPKO Health's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPK vs PSNL, CDNA, CSTL: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, OPKO Health's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OPKO Health Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where OPKO Health's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPKO Health (OPK) has a Buyback Yield % of 4.47 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on OPKO Health and its competitors. This is 21% below median its historical median of 5.68. According to the industry distribution chart, OPKO Health ranks #5 out of 89 companies in the Medical Diagnostics & Research industry, placing it in the top 5.6%.
Is OPKO Health's Buyback Yield % too high?
OPKO Health's current Buyback Yield % of 4.47 is 21% below median its 10-year median of 5.68. Based on the distribution chart, OPKO Health ranks #5 out of 89 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, OPKO Health has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OPKO Health's Buyback Yield % compare to PSNL and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, OPKO Health ranks #5 out of 89 companies for Buyback Yield %. This places OPKO Health in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on OPKO Health and its competitors. OPKO Health's current Buyback Yield % is 4.47, which is 21% below median its own 10-year median of 5.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OPKO Health stock overvalued right now?
Based on GuruFocus' analysis, OPKO Health (OPK) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $1.52 — trading 43.4% above its estimated fair value. The current Buyback Yield % is 4.47, which is 21% below median its 10-year median of 5.68. OPKO Health's overall GF Score™ is 52/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For OPKO Health (OPK), the current Buyback Yield % is 4.47 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OPKO Health (OPK) Overvalued in 2026?
Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued.
The current stock price of $1.52 is trading 43.4% above its estimated GF Value™ of $1.06.
GuruFocus considers OPKO Health to be Significantly Overvalued.
Key valuation signals for OPK:
Buyback Yield %: 4.47 (21% below median its 10-year median of 5.68)
GF Value™: $1.06 vs. price of $1.52 (43.4% above fair value)
No single metric tells the full story. See the OPK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
52GF Score
Get the complete analysis for OPK
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPK has been successfully added to your 
